Clinical Features, Etiology and Outcomes of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease

被引:42
作者
Gomez-Junyent, Joan [1 ,2 ]
Garcia-Vidal, Carolina [1 ,2 ,5 ]
Viasus, Diego [1 ,2 ,5 ]
Millat-Martinez, Pere [1 ,2 ]
Simonetti, Antonella [1 ,2 ]
Santos, Ma Salud [2 ,3 ]
Ardanuy, Carmen [2 ,4 ]
Dorca, Jordi [2 ,3 ,5 ]
Carratala, Jordi [1 ,2 ,5 ]
机构
[1] Univ Barcelona, Hosp Univ Bellvitge, Dept Infect Dis, Barcelona, Spain
[2] Inst Invest Biomed Bellvitge IDIBEL, Barcelona, Spain
[3] Univ Barcelona, Hosp Univ Bellvitge, Dept Resp Med, Barcelona, Spain
[4] Univ Barcelona, Hosp Univ Bellvitge, Dept Microbiol, Barcelona, Spain
[5] Inst Salud Carlos III, Spanish Network Res Infect Dis, REIPI, Madrid, Spain
关键词
PRIOR PNEUMOCOCCAL VACCINATION; INHALED CORTICOSTEROID USE; HOSPITALIZED ADULTS; COPD PATIENTS; RISK-FACTORS; MORTALITY; COMPLICATIONS; EPIDEMIOLOGY; BURDEN; STAY;
D O I
10.1371/journal.pone.0105854
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Community-acquired pneumonia (CAP) is a frequent complication of chronic obstructive pulmonary disease (COPD), but previous studies are often contradictory. Objectives: We aimed to ascertain the characteristics and outcomes of CAP in patients with COPD as well as to determine the risk factors for mortality and Pseudomonas aeruginosa pneumonia in COPD patients with CAP. We also describe the etiology and outcomes of CAP in COPD patients receiving chronic oxygen therapy at home and those receiving inhaled steroids. Methods: An observational analysis of a prospective cohort of hospitalized adults with CAP (1995-2011) was performed. Results: We documented 4121 CAP episodes, of which 983 (23.9%) occurred in patients with COPD; the median FEV1 value was 50%, and 57.8% were classified as stage III or IV in the GOLD classification. Fifty-eight per cent of patients were receiving inhaled steroids, and 14.6% chronic oxygen therapy at home. Patients with COPD presented specific clinical features. S. pneumoniae was the leading causative organism overall, but P. aeruginosa was more frequent in COPD (3.4 vs. 0.5%; p < 0.001). Independent risk factors for case-fatality rate in patients with COPD were multilobar pneumonia, P. aeruginosa pneumonia, and high-risk PSI classes. Prior pneumococcal vaccination was found to be protective. FEV1 was an independent risk factor for P. aeruginosa pneumonia. Conclusions: CAP in patients with COPD presents specific characteristics and risk factors for mortality. Prior pneumococcal vaccine has a beneficial effect on outcomes. P. aeruginosa pneumonia is associated with low FEV1 values and poor prognosis.
引用
收藏
页数:10
相关论文
共 43 条
[1]  
[Anonymous], 1997, MMWR Recomm Rep, V46, P1
[2]  
[Anonymous], 2013, GLOB STRAT DIAGN MAN
[3]   Chronic obstructive pulmonary disease: molecular and cellular mechanisms [J].
Barnes, PJ ;
Shapiro, SD ;
Pauwels, RA .
EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (04) :672-688
[4]   International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study [J].
Buist, A. Sonia ;
McBurnie, Mary Ann ;
Vollmer, William M. ;
Gillespie, Suzanne ;
Burney, Peter ;
Mannino, David M. ;
Menezes, Ana M. B. ;
Sullivan, Sean D. ;
Lee, Todd A. ;
Weiss, Kevin B. ;
Jensen, Robert L. ;
Marks, Guy B. ;
Gulsvik, Amund ;
Nizankowska-Mogilnicka, Ewa .
LANCET, 2007, 370 (9589) :741-750
[5]   Bacteraemic pneumococcal pneumonia in COPD patients: better outcomes than expected [J].
Calbo, E. ;
Valdes, E. ;
Ochoa de Echagueen, A. ;
Fleites, A. ;
Molinos, L. ;
Xercavins, M. ;
Freixas, N. ;
Rodriguez-Carballeira, M. ;
Garau, J. .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2009, 28 (08) :971-976
[6]   Epidemiology and costs of chronic obstructive pulmonary disease [J].
Chapman, KR ;
Mannino, DM ;
Soriano, B ;
Vermeire, PA ;
Buist, AS ;
Thun, MJ ;
Connell, C ;
Jemal, A ;
Lee, TA ;
Miravitlles, M ;
Aldington, S ;
Beasley, R .
EUROPEAN RESPIRATORY JOURNAL, 2006, 27 (01) :188-207
[7]   Observational Study of Inhaled Corticosteroids on Outcomes for COPD Patients with Pneumonia [J].
Chen, Dennis ;
Restrepo, Marcos I. ;
Fine, Michael J. ;
Pugh, Mary Jo V. ;
Anzueto, Antonio ;
Metersky, Mark L. ;
Nakashima, Brandy ;
Good, Chester ;
Mortensen, Eric M. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (03) :312-316
[8]   Cardiac Complications in Patients With Community-Acquired Pneumonia Incidence, Timing, Risk Factors, and Association With Short-Term Mortality [J].
Corrales-Medina, Vicente F. ;
Musher, Daniel M. ;
Wells, George A. ;
Chirinos, Julio A. ;
Chen, Li ;
Fine, Michael J. .
CIRCULATION, 2012, 125 (06) :773-U92
[9]   Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results [J].
Crim, C. ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Willits, L. R. ;
Yates, J. C. ;
Vestbo, J. .
EUROPEAN RESPIRATORY JOURNAL, 2009, 34 (03) :641-647
[10]   Systemic Inflammatory Pattern of Patients With Community-Acquired Pneumonia With and Without COPD [J].
Crisafulli, Ernesto ;
Menendez, Rosario ;
Huerta, Arturo ;
Martinez, Raquel ;
Montull, Beatriz ;
Clini, Enrico ;
Torres, Antoni .
CHEST, 2013, 143 (04) :1009-1017